Red Flags at Repros Therapeutics

“What's in a name? That which we call a rose, By any other word would smell as sweet.” -- William Shakespeare in Romeo and Juliet

Does an old discarded penny stock traded under a flashy new name smell sweeter to investors? Apparently so. Shares of Repros Therapeutics (RPRX) have risen sharply, more than doubling since September of last year. However, I wonder if many shareholders in Repros have forgotten, or maybe never learned, that Repros is the same corporation as the discredited and oft-sued Zonagen. In 2006, after numerous failures, Zonagen changed its name to Repros and hoped to shove two decades of failure under the rug. Well, it's past time to go looking in the closet to see what sort of things Zonagen and its long-time CEO Joesph Podolski might not want you to know.